Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide plus R-GDP in relapsed/refractory diffuse large B-cell lymphoma
2014-001620-29Phase 2Active
- Sponsor
- GELTAMO
- Start
- Jul 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide, rituximab, gemcitabine, dexamethasone and cisplatin in diffuse large B-cell lymphoma (DLBCL), sponsored by GELTAMO. Primary endpoint: Overall Response Rate. Started Jul 2014; status: active.
02
Drugs
lenalidomiderituximabgemcitabinedexamethasonecisplatin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2014-001620-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001620-29.